ファイザー社は第2四半期の予想を上回り,2025年の予測を上げ,主要な治療に注力しています. Pfizer beat Q2 earnings estimates, raised 2025 guidance, and focuses on key therapies.

ファイザーは2025年8月5日に、EPSが0.78ドル、売上高が146億5,000万ドルで、予想を0.20ドル上回り、前年同期比10.3%増の好調な第2四半期収益を報告しました。 Pfizer reported strong Q2 earnings on August 5, 2025, with $0.78 EPS and $14.65 billion in revenue, exceeding estimates by $0.20 and rising 10.3% year-over-year. 会社は2025年度の全収入ガイドブックを1株あたり2.90ドルから3.10ドルに上げた. The company raised its 2025 full-year earnings guidance to $2.90–$3.10 per share. 機関投資家は混合的な活動を示した. Capricorn Fund Managersは株式を8.5%削減し,Grassi Investment Managementは株式を1.8%削減し,Stock Yards Bank & Trustは551株のポジションを増やした. Institutional investors showed mixed activity, with Capricorn Fund Managers reducing its stake by 8.5% and Grassi Investment Management cutting its holding by 1.8%, while Stock Yards Bank & Trust increased its position by 551 shares. 株式は27.37ドル近くで取引され,市場資本は1億5500億円,P/eの比率は14.56ドル,合意額は"保留". The stock traded near $27.37, with a market cap of $155.59 billion, a P/E ratio of 14.56, and a consensus "Hold" rating. ファイザー社は,コミナティ,パクスロビッド,エリキス,ヌルテックODTを含む,心臓血管,感染症,COVID-19治療に引き続き注力しています. Pfizer continues to focus on cardiovascular, infectious disease, and COVID-19 treatments, including Comirnaty, Paxlovid, Eliquis, and Nurtec ODT.